세계의 피하 약물전달 디바이스 시장 예측(-2030년) : 제품 유형, 적응증, 유통 채널 및 지역별 세계 분석

According to Stratistics MRC, the Global Subcutaneous Drug Delivery Devices Market is accounted for $30.9 billion in 2023 and is expected to reach $65.4 billion by 2030 growing at a CAGR of 11.3% during the forecast period. Medical equipment called subcutaneous drug delivery devices is used to give patients medication subcutaneously, or under the skin. This method of drug delivery is preferred over others because it enables the drug's constant and continuous release into circulation, leading to less side effects and more consistent therapeutic advantages. Subcutaneous drug delivery systems consist of a syringe inserted under the skin, a distribution system, and a pharmaceutical container.

According to the National Multiple Sclerosis Society, an estimated 1.0 million adults were reported to be living with multiple sclerosis in the U.S. in 2017.

Market Dynamics:

Driver:

Rise in Chronic Diseases

Increasing prevalence of chronic diseases such as diabetes, autoimmune disorders, and cardiovascular conditions has driven the demand for subcutaneous drug delivery devices. These devices offer an effective way to administer medication for long-term management of these ailments. Therefore, the rapidly growing prevalence of chronic diseases is expected to drive the growth of the market.

Restraint:

Lack of health awareness

In emerging and undeveloped economies, there's a dearth of knowledge about pharmaceuticals, various ailments, and drug delivery technologies. Chronic illness-related fatalities rise as a result of inadequate healthcare facilities. Most rural residents continue to go undetected and untreated. Furthermore, the use of subcutaneous drug delivery devices is limited in a number of countries by the high cost of medications and drug administration equipment. This is a significant element that might impede market expansion.

Opportunity:

Growing demand for biosimilar and biologics

The market participants in the worldwide subcutaneous drug delivery devices market have a number of growth opportunities thanks to the quick rise in popularity of biologic and biosimilar medications. Global demand for subcutaneous drug delivery systems is being driven by the increasing need for different medications to treat chronic conditions. The growing use of biologics and biosimilars, which often require subcutaneous administration, has bolstered the demand for specialized delivery devices tailored for these medications.

Threat:

Improper use may give rise to needle stick injuries

Needlestick injuries and drug overdoses are only two of the issues that can arise from using subcutaneous medication delivery devices improperly without the right information and instruction. This can make it more difficult for the patients to choose between several drug delivery options. Furthermore, the dangers of blood-borne infections linked to injection needles might end up being a significant obstacle.

COVID-19 Impact:

The market for subcutaneous medication delivery devices has been significantly impacted by the COVID-19 epidemic, as has the whole healthcare sector. Self-administration devices are becoming more and more in demand as a result of the growing emphasis on home-based treatment, remote healthcare, and reducing hospital visits. The epidemic has brought attention to the significance of efficient medication delivery techniques, spurring innovation and investment in the subcutaneous drug delivery market.

The wearable injectors segment is expected to be the largest during the forecast period

The wearable injectors segment is expected to be the largest during the forecast period. This is linked to the increase in needle stick injuries as well as the increased risk of blood-borne illnesses from injection usage. The high-viscosity, high-volume biologic medications are administered with exceptional efficiency by the wearable injectors. Digital medicine administration tools called wearable injectors are convenient and assist patients in giving precise dosages at the appropriate times.

The neurological disorders segment is expected to have the highest CAGR during the forecast period

The neurological disorders segment is expected to have the highest CAGR during the forecast period. These devices can provide a controlled and steady release of medications over an extended period. For neurological disorders where consistent medication levels are crucial, such as in epilepsy or Parkinson's disease, this controlled release can help manage symptoms effectively. These devices are often designed for patient comfort, minimizing the invasiveness of treatments.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the increased prevalence of various chronic diseases resulted in the huge demand for drugs and drug delivery devices amongst the population. The market is growing due to a number of significant reasons, including the presence of improved healthcare infrastructure, the presence of multiple major manufacturers in the region and the different developmental strategies they have followed, and rising healthcare spending.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. This is majorly attributed to the rapidly growing diabetic population in the region owing to the unhealthy food habits of the people. The rising disposable income, growing awareness regarding the diabetes management, and rising healthcare expenditure are the major factors that will drive the growth of the market in the forthcoming future.

Key players in the market:

Some of the key players in Subcutaneous Drug Delivery Devices market include Medtronic Plc, Gerresheimer AG, Elcam Medical Group, Insulet Corporation, Ypsomed AG, Becton, Dickinson and Company, PharmaJet, Unilife Corporation, In life Sciences , West Pharmaceutical Services, Inc., Novo Nordisk, Eli Lilly, Merck, AstraZeneca, Amgen, Enable Injections, Consort Medical Plc and Wilhelm Haselmeier GmbH & Co. KG.

Key Developments:

In November 2023, The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

In October 2023, Eli Lilly gives $20M upfront cash injection to Elektrofi in next-gen subcutaneous drug collab. Eli Lilly has tapped up drug delivery specialist Elektrofi to see whether the biotech's microparticle formulation technology could produce the next generation of subcutaneously administered therapies.

Products Covered:

• Prefilled Syringes
• Auto-Injectors
• Wearable Injectors
• Pen Injectors
• Needle-Free Injectors
• Other Products

Types Covered:

• Disposable
• Reusable

Indications Covered:

• Neurological Disorders
• Oncology Disorders
• Auto-immune Disorders
• Ophthalmic Disorders
• Allergy & Infectious Disorders
• Hormonal Disorders
• Other Indications

Distribution Channels Covered:

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Subcutaneous Drug Delivery Devices Market, By Product

• 5.1 Introduction
• 5.2 Prefilled Syringes
• 5.3 Auto-Injectors
• 5.4 Wearable Injectors
• 5.5 Pen Injectors
• 5.6 Needle-Free Injectors
• 5.7 Other Products

6 Global Subcutaneous Drug Delivery Devices Market, By Type

• 6.1 Introduction
• 6.2 Disposable
• 6.3 Reusable

7 Global Subcutaneous Drug Delivery Devices Market, By Indication

• 7.1 Introduction
• 7.2 Neurological Disorders
• 7.3 Oncology Disorders
• 7.4 Auto-immune Disorders
• 7.5 Ophthalmic Disorders
• 7.6 Allergy & Infectious Disorders
• 7.7 Hormonal Disorders
• 7.8 Other Indications

8 Global Subcutaneous Drug Delivery Devices Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Retail Pharmacies
• 8.4 Online Pharmacies
• 8.5 Other Distribution Channels

9 Global Subcutaneous Drug Delivery Devices Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Medtronic Plc
• 11.2 Gerresheimer AG
• 11.3 Elcam Medical Group
• 11.4 Insulet Corporation
• 11.5 Ypsomed AG
• 11.6 Becton, Dickinson and Company
• 11.7 PharmaJet
• 11.8 Unilife Corporation
• 11.9 In life Sciences
• 11.10 West Pharmaceutical Services, Inc.
• 11.11 Novo Nordisk
• 11.12 Eli Lilly
• 11.13 Merck
• 11.14 AstraZeneca
• 11.15 Amgen
• 11.16 Enable Injections
• 11.17 Consort Medical Plc
• 11.18 Wilhelm Haselmeier GmbH & Co. KG